Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials

Zhang,Jian; Zhang,Weiqing; Huang,Shaohong; Li,Hui; Li,Yun; Chen,Huiguo; Wu,Weibing; Zhou,Wei; Wang,Cuiping; Liao,Hongying; Gu,Lijia

doi:10.3892/etm.2012.690

Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials

Authors:
- Jian Zhang
- Weiqing Zhang
- Shaohong Huang
- Hui Li
- Yun Li
- Huiguo Chen
- Weibing Wu
- Wei Zhou
- Cuiping Wang
- Hongying Liao
- Lijia Gu
View Affiliations

Affiliations: Thoracic Surgery Department and Clinical Research Center for Thoracic Oncology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, P.R. China
Published online on: August 31, 2012 https://doi.org/10.3892/etm.2012.690
Pages: 849-858

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance therapy in patients with unresectable non-small cell lung cancer (NSCLC) by evidence‑based methodology. Six eligible studies including 4,372 patients were analyzed. Erlotinib was administered to 2,191 patients as maintenance treatment, while the remaining patients received a placebo or observation only. The meta‑analysis was performed using Reviewer Manager Version 5.12 software. Compared with the control group, maintenance erlotinib improved progression-free survival (PFS) and overall survival (OS) with moderate heterogeneity. Results from the random effects model analysis for OS were not in concordance with the difference observed in the fixed effects model analysis. Administration of erlotinib only after chemotherapy obtained a higher objective response rate (ORR). Safety analyses indicated a slight increase in side-effects. The most common adverse events (AEs) were diarrhea and rash, which were usually manageable. There was no significant difference in treatment-related deaths. Erlotinib produced significant clinical benefits with acceptable toxicity as a maintenance strategy in patients with unresectable NSCLC, particularly when sequentially administered with chemotherapy. However, more well-designed randomized control trials (RCTs) are required to identify patients that may derive greater benefits from maintenance with erlotinib, and whether the use of erlotinib as maintenance therapy is more efficient than second‑line treatment should also be investigated.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics. CA Cancer J Clin. 58:71–96. 2008.
2	Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 24:4539–4544. 2006.PubMed/NCBI
3	Stinchcombe TE, Bogart J, Wigle DA and Govindan R: Annual review of advances in lung cancer clinical research: a report for the year 2009. J Thorac Oncol. 5:935–939. 2010.PubMed/NCBI
4	Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol. 22:330–353. 2004. View Article : Google Scholar : PubMed/NCBI
5	Park JO, Kim SW, Ahn JS, et al: Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol. 25:5233–5239. 2007. View Article : Google Scholar : PubMed/NCBI
6	Socinski MA, Schell MJ, Peterman A, et al: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small cell lung cancer. J Clin Oncol. 20:1335–1343. 2002. View Article : Google Scholar
7	von Plessen C, Bergman B, Andresen O, et al: Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small cell lung cancer. Br J Cancer. 95:966–973. 2006.PubMed/NCBI
8	Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 374:1432–1440. 2009. View Article : Google Scholar : PubMed/NCBI
9	Fidias PM, Dakhil SR, Lyss AP, et al: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol. 27:591–598. 2009. View Article : Google Scholar : PubMed/NCBI
10	Belani CP, Barstis J, Perry MC, et al: Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 21:2933–2939. 2003. View Article : Google Scholar : PubMed/NCBI
11	Pirker R, Pereira JR, Szczesna A, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 373:1525–1531. 2009. View Article : Google Scholar : PubMed/NCBI
12	Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
13	Stinchcombe TE and Socinski MA: Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol. 4:243–250. 2009. View Article : Google Scholar : PubMed/NCBI
14	Gridelli C, Maione P, Rossi A, et al: Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist. 14:137–147. 2009. View Article : Google Scholar : PubMed/NCBI
15	Butts C, Murray N, Maksymiuk A, et al: Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small cell lung cancer. J Clin Oncol. 23:6674–6681. 2005. View Article : Google Scholar : PubMed/NCBI
16	Cappuzzo F, Ciuleanu T, Stelmakh L, et al SATURN investigators: Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 11:521–529. 2010. View Article : Google Scholar : PubMed/NCBI
17	Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
18	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
19	Reck M, van Zandwijk N, Gridelli C, et al: Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV tarceva lung cancer survival treatment study. J Thorac Oncol. 5:1616–1622. 2010. View Article : Google Scholar : PubMed/NCBI
20	Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 25:1545–1552. 2007. View Article : Google Scholar : PubMed/NCBI
21	Herbst RS, Prager D, Hermann R, et al TRIBUTE Investigator Group: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol. 23:5892–5899. 2005. View Article : Google Scholar
22	NHS Centre for Reviews and Dissemination: Undertaking systematic reviews of research on effectiveness: CRD’s guidance for carrying out or commissioning reviews. CRD Report 4. 2nd edition. University of York; York: 2001
23	Parmar MK, Torri V and Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 17:2815–2834. 1998. View Article : Google Scholar : PubMed/NCBI
24	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
25	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
26	Altman DG and Deeks JJ: Meta-analysis, Simpson’s paradox, and the number needed to treat. BMC Med Res Methodol. 2:32002.
27	McQuay HJ and Moore RA: Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 126:712–720. 1997. View Article : Google Scholar : PubMed/NCBI
28	Smeeth L, Haines A and Ebrahim S: Numbers needed to treat derived from meta-analyses–sometimes informative, usually misleading. BMJ. 318:1548–1551. 1999.
29	Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D and Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 354:1896–1900. 1999. View Article : Google Scholar : PubMed/NCBI
30	Mok TS, Wu YL, Yu CJ, et al: Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 27:5080–5087. 2009. View Article : Google Scholar : PubMed/NCBI
31	Kabbinavar FF, Miller VA, Johnson BE, O’Connor PG and Soh C; ATLAS Investigators: Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol (meeting abstracts). 28:75262010.
32	Perol M, Chouaid C, Milleron BJ, et al: Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol (meeting abstracts). 28:75072010.
33	Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH and Gandara DR: Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small cell lung cancer. Clin Lung Cancer. 7:385–388. 2006. View Article : Google Scholar : PubMed/NCBI
34	Piperdi B, Ling YH and Perez-Soler R: Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small-cell lung cancer cell lines. J Thorac Oncol. 2:715–721. 2007. View Article : Google Scholar : PubMed/NCBI
35	Higgins B, Kolinsky K, Smith M, et al: Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs. 15:503–512. 2004. View Article : Google Scholar : PubMed/NCBI